Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small-cell lung cancer by Toge Masyoshi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY  46:  1844-1848,  20151844
Abstract. Non-small cell lung cancer (NSCLC) is one of the 
leading causes of death in all lung cancer patients due to its 
metastatic spread. Even though cisplatin treatment after surgical 
resection of the primary tumor has been established as a standard 
chemotherapy for residual disease including metastatic spread, 
NSCLC often acquires a resistance against chemotherapy, and 
metastatic disease is often observed. Amongst many potential 
mechanisms, epithelial-to-mesenchymal transition (EMT) has 
been considered as an important process in acquiring both 
metastatic spread and chemo-resistance of NSCLC. In this 
study, we identified MCL-1 as a critical molecule for chemo-
resistance in A549 cells associated with TGF-β-induced EMT. 
Importantly, downregulation of MCL-1 by siRNA or inhibition 
of MCL-1 with pan-BCL2 inhibitor to inhibit MCL-1 was able 
to overcome the EMT-associated chemo-resistance in A549 
cells. Collectively, MCL-1 can be a new therapeutic target 
for overcoming EMT-associated chemo-resistance in NSCLC 
patients in the context of post-operative chemotherapies.
Introduction
Non-small cell lung cancer (NSCLC) is one of the common 
causes of death in the world (1). Although cisplatin treatment 
after surgery is known as a standard and effective chemo-
therapy, metastatic spread in NSCLC patients often occurs 
(2-4). In addition, it is still controversial whether an adjuvant 
chemotherapy with cisplatin gives a significant survival 
advantage in stage I NSCLC patients compared with surgery 
alone (5-7). This may lead to the possibility that metastatic 
NSCLCs already acquire resistance to chemotherapy during 
tumor progression.
Cancer metastasis is one of the major causes of the high 
mortality rate in cancer patients and it consists of multiple 
biological steps, such as dissemination from primary tumor, 
intravasation, attachment to vessel of target tissue, extravasa-
tion, angiogenesis, and subsequent growth at the metastasis site 
(8). Some of these biological steps have been shown to be related 
to epithelial-to-mesenchymal transition (EMT) (9-12). Although 
EMT also has been shown to limit the sensitivities of cancer cells 
to chemotherapeutic drugs (13,14), the potential mechanism by 
which cancer cells acquire resistance to anticancer drugs associ-
ated with the EMT process is not well defined.
In this study, we demonstrated that EMT in human 
NSCLC cell line A549 induced by TGF-β treatment limits the 
sensitivities to various anticancer drugs, and further identified 
MCL-1 as a critical molecule of such EMT-associated chemo-
resistance of A549 cells. Importantly, we showed that targeting 
MCL-1 by siRNA delivery or the pan-BCL2 inhibitor treat-
ment could overcome the EMT-associated chemo-resistance 
in A549 cells.
Materials and methods
Reagents and plasmids. The reagents used were recombinant 
human TGF-β from Peprotech (London, UK), obatoclax 
from Selleck Chemicals (Houston, TX, USA), ABT-737 from 
AdooQ BioScience (Irvine, CA, USA), cisplatin, vinorelbine, 
gemcitabine and paclitaxel from Wako Pure Chemical Industries 
(Osaka, Japan). siRNAs against MCL-1 (L-004501-00, 
J-004501-16, and J-004501-17), Bcl2A1 (L-003306-00), and 
control (D-00181-02) siRNA were purchased from Thermo 
Fisher Scientific (Rockford, IL, USA). The human MCL-1 
cDNA was amplified from normal human cDNA and subcloned 
into pcDNA3.1-HA (from David E. Fisher, MGH, MA, USA).
Cell cultures. Human lung adenocarcinoma A549 cells were 
cultured in RPMI-1640 medium (Life Technologies Corp., 
Carlsbad, CA, USA) with 10% fetal bovine serum (FBS; 
ICN Biomedicals, Aurora, OH, USA), 2 mM L-glutamine 
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(Life Technologies Corp.), 100 U/ml penicillin and 100 µg/ml 
streptomycin in 5% CO2 at 37˚C. A549 cells stably expressing 
MCL-1 or vector control were established by transfecting 
pcDNA3.1-HA/MCL-1 or pcDNA3.1 under G418 (1 mg/ml). For 
siRNA transfection, each 25 nM of siRNAs was reverse-trans-
fected using Lipofectamine™ RNAiMAX (Life Technologies 
Corp.) following the manufacturer's instructions, and the trans-
fected cells were used for each experiment.
Cell viability assay. Cell viability was quantified using the cell 
proliferation reagent WST-1 (Dojindo, Japan) or CellTiter-Glo 
(Promega, Madison, WI, USA). A549 cells, siRNA-reverse 
transfected A549 cells, or stable MCL-1 expressing A549 cells 
were incubated for 24 h. The antitumor drugs were then added 
after pre-treatment with TGF-β for 48 h. After additional incu-
bation for the indicated time, WST-1 solution or CellTiter-Glo 
reagent was added. Absorbance was measured at 450 nm using 
a Microplate reader for WST-1 assay and luminescence was 
measured using a GloMax Multi-detection system (Promega) 
for CellTiter-Glo assay. The cell viability was determined as 
percent viability compared with the vehicle control.
Western blot analysis. Whole cell lysates were prepared 
as described previously (15). The primary antibodies used 
were E-cadherin, N-cadherin, Snail, MCL-1, BCL2A1/Bfl-1, 
BCL-xL, PARP and caspase-3 (Cell Signaling Technology, 
Beverly, MA, USA), hemagglutinin (HA) (Roche, Indianapolis, 
IN, USA) and β-actin (Santa Cruz Biotechmology, Santa Cruz, 
CA, USA). All antibodies were used by x2000 dilution.
Real-time RT-PCR. Expression of MCL-1 and BCL2A1 
mRNA was quantitatively determined by real-time PCR on an 
ABI PRISM 7300 Real Time PCR System (Life Technologies 
Corp.). Total RNAs were prepared using the RNeasy Plus 
Mini kit (Qiagen, Hilden, Germany). Expression level of the 
targeted mRNAs was normalized to β-actin mRNA. The 
primers used were: 5'-TCG TAA GGA CAA AAC GGG 
AC-3' (sense) and 5'-CAT TCC TGA TGC CAC CTT CT-3' 
(antisense) for MCL-1 mRNA, 5'-CCC GGA TGT GGA TAC 
CTA TAA GGA GA-3' (sense) and 5'-GTC ATC CAG CCA 
GAT TTA GGT TCA-3' (antisense) for BCL2A1 mRNA, and 
5'-GCA CAG AGC CTC GCC TT-3' (sense) and 5'-GTT GTC 
GAC GAC GAG CG-3' (antisense) for β-actin mRNA.
Apoptosis assay. Apoptotic cell number was determined 
using the MUSE Annexin V and Dead Cell kit (Merck KGaA, 
Darmstadt, Germany) according to the manufacturer's instruc-
tions. Briefly, the stable cells were harvested after being treated 
with cisplatin and diluted with PBS containing 1% bovine 
serum albumin (BSA) as a dilution buffer to a concentration 
of 5x105 cells/ml. Cell suspension (100 µl) was then added to 
100 µl MUSE Annexin V and Dead Cell reagent (2x dilution), 
incubated for 20 min at room temperature, and analyzed using 
the MUSE Cell Analyzer. Total Annexin V-positive cells were 
determined as apoptotic cells.
Results
Acquired chemo-resistance in A549 cells associates with 
TGF-β-induced EMT. Although the relationship between 
epithelial-to-mesenchymal transition (EMT) and chemo-
resistance has been implicated (14,16), the detailed molecular 
mechanism of such EMT-accompanying chemo-resistance 
has not been determined yet. Therefore, we first tested tthe 
various antitumor reagents, such as cisplatin, paclitaxel, 
gemcitabine, and vinorelbine, in A549 lung adenocarcinoma 
cell lines with or without inducing EMT by pre-treating with 
5 ng/ml TGF-β (11,17). Consistent with our previous studies 
(17,18), A549 pre-treated with TGF-β showed EMT phenotype 
in both cell morphology and expression of protein markers 
such as E-cadherin reduction and N-cadherin induction (data 
not shown). In concert with EMT-induction, A549 cells pre-
treated with TGF-β showed significant resistance against all 
anticancer reagents tested (Fig. 1A and Table I), which was 
associated with the reduction of apoptosis marker expression 
(Fig. 1B). These findings indicate that A549 cells acquired a 
wide spectrum of chemo-resistance, possibly through apop-
tosis inhibition associated with EMT induced by TGF-β.
Figure 1. TGF-β induces chemo-resistance in A549 cells. (A) A549 cells 
were incubated with or without 5 ng/ml TGF-β for 48 h, shown as TGF-β 
or (-), respectively. Followed by the treatment with the indicated concentra-
tions of cisplatin for 48 h, cell viability was determined by WST-1 assay. Cell 
viability was normalized to that in each non-cisplatin-treated cell. **p<0.01 
vs. non-TGF-β treatment at each time-point by two-way ANOVA followed 
by the Bonferroni post-hoc test. (B) Whole cell lysates were subjected to 
western blotting. Other conditions were similar to (A).
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Critical role of MCL-1 in A549 chemo-resistance associated 
with TGF-β-induced EMT. We next investigated the expres-
sion levels of BCL2 family members in EMT-induced A549 
cells. The members are related to chemo-resistance in various 
cancers by inhibiting apoptosis (15,19,20). Amongst many of 
BCL2 family members, the expression of MCL-1 and BCL2A1 
were specifically increased associated with TGF-β-induced 
EMT in A549 cells in a time-dependent manner (Fig. 2A). We 
further confirmed the increased mRNA expression of MCL-1 
and BCL2A1 after TGF-β treatments (Fig. 2B) consistent with 
their protein expression.
In order to further investigate whether either MCL-1 or 
BCL2A1 is required for EMT-associated chemo-resistance, we 
employed gene knock-down of MCL-1 or BCL2A1 by using 
siRNA pools in which four different siRNAs are contained. 
MCL-1 knock-down rescued the sensitivity to cisplatin 
treatment in EMT-induced A549 cells contrary to BCL2A1 
knock-down which did not show any significant effect (Fig. 3A). 
Similar results were also confirmed in additional experi-
ments using two siRNAs against MCL-1 with different target 
sequences (Fig. 3B). Furthermore, MCL-1-overexpression was 
able to significantly suppress the cisplatin-induced apoptosis in 
non-EMT-induced parental A549 cells (Fig. 3C). Collectively, 
these results strongly support the critical contribution of 
MCL-1 in acquiring EMT-associated chemo-resistance in 
A549 cells.
MCL-1 inhibition by pan-BCL2 inhibitor treatment overcomes 
TGF-β-induced chemo-resistance. To test the clinical applica-
tion of our findings, we examined the effects of pan-BCL2 
inhibitors in EMT-associated chemo-resistance in A549 cells. 
As shown in Fig. 4A, obatoclax, which has a broad range 
of inhibition in BCL2 family members including MCL-1, 
re-sensitized EMT-induced A549 cells to cisplatin toxicity. 
Of note, the treatment with obatoclax (100 nM) showed only 
minor effect on TGF-β-treated A549 cell viability (Fig. 4A). 
In accordance with re-sensitizing to cisplatin toxicity, we 
also detected the cleavage of both caspase-3 and PARP in the 
combination of obatoclax with cisplatin in EMT-induced A549 
cells by TGF-β (Fig. 4B). Collectively, these results implicate 
a clinical advantage for targeting MCL-1 in EMT-associated 
cisplatin-resistance in A549 cells.
Discussion
In this study, we demonstrated that human NSCLC A549 
acquired chemo-resistance upon TGF-β-induced EMT and 
such EMT-associated chemo-resistance was mediated through 
MCL-1-dependent anti-apoptotic pathway. By treating with 
pan-BCL2 inhibitor, obatoclax, EMT-associated chemo-
resistance in A549 cells can be reversed, therefore we propose 
that pharmacological inhibition of MCL-1 could be an attrac-
tive target to overcome EMT-associated chemo-resistance and 
further inhibit metastasis spread in NSCLC patients.
Although MCL-1 was a key molecule in EMT-associated 
chemo-resistance in this study (Fig. 3), other BCL-2 family 
members are known to contribute for chemo-resistance in 
general. For example, enhanced BCL-2 expression is involved 
in nicotine- or matrilysin-induced cisplatin-resistance in lung 
cancer cells (21,22) and BCL2A1 confers resistance to BRAF 
inhibitors in melanoma (15). Considering other EMT inducers 
Table I. IC50 of various anticancer drugs in TGF-β-induced 
chemo-resistance.
 IC50a (mean ± SD) -------------------------------------------------------------
 A549 A549/TGF-β
Cisplatin (µM)   7.6±0.8 10.6±0.8b
Paclitaxel (nM) 11.1±1.1 22.4±7.4b
Gemcitabine (µM) 0.75±0.2 >40b
Vinorelbine (nM) 15.8±3.0 29.1±6.9b
aInhibitory concentration at 50% (IC50) was determined by WST-1 
assay at 48 h. The values were calculated with data from at least three 
independent experiments. bp<0.05 compared with A549 cells.
Figure 2. TGF-β induces MCL-1 and BCL2A1 in A549 cells. (A) A549 cells were incubated with 5 ng/ml TGF-β for the indicated time. Whole cell lysates 
were subjected to western blotting. Other conditions were similar to Fig. 1B. (B) A549 cells were treated with 5 ng/ml TGF-β for the indicated times. MCL-1 
(left panel) and BCL2A1 (right panel) mRNA were quantified by real-time RT-PCR. Relative mRNA expression was normalized to the value of each mRNA 
at 0 h. Data are shown as the mean ± SD of three independent experiments. **p<0.01 or *p<0.05 vs. mRNA expression at 0 h by one-way ANOVA followed by 
the Bonferroni post-hoc test.
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in tumor microenvironment, EGF or HGF, have been reported 
to induce both EMT and MCL-1 expression (20,23-26), MCL-1 
induction might be a common mechanism for EMT-associated 
chemo-resistance. Although we do not show any direct connec-
tion between TGF-β and MCL-1, there are several reports 
that the EMT-related transcription factors, zEB1 or Twist1, 
can regulate MCL-1 expression (27,28). In this context, we 
observed the induction of zEB1 expression in A549 cells after 
TGF-β treatment (data not shown). Collectively, these observa-
tions suggest that zEB1-mediated transcriptional control can 
be involved in EMT-associated chemo-resistance by regulating 
MCL-1 expression. Nevertheless, our current results implicate 
that mesenchymal-transitioned NSCLC could acquire the 
chemo-resistance through the induction of MCL-1. Consistent 
Figure 3. MCL-1 is essential and sufficient to TGF-β-induced chemo-resistance. (A) A549 cells were transefected with control siRNA pool (siControlp) or 
siRNA pool against MCL-1 (siMCL-1p) or BCL2A1 (siBCL2A1p). At 24 h after transfection, 5 ng/ml TGF-β was added and cells were cultured for 48 h. Then 
the cells were exposed to cisplatin for 24 h (western blotting) or 48 h (WST-1 assay). **p<0.01 compared to siControl pool with TGF-β and cisplatin by one-way 
ANOVA followed by the Bonferroni post-hoc test. (B) A549 cells were transefected with control siRNA (siControl) or siRNA against MCL-1 (siMCL-1#1 
and siMCL-1#2). Other conditions are similar to (A). (C) A549 cells stably overexpressing HA/MCL-1 (HA/MCL-1) or polypeptides (polyP) were exposed to 
cisplatin for 24 h (western blotting) or 48 h (Annexin V and Dead Cell assay). **p<0.01 compared with polyP with cisplatin by two-way ANOVA followed by 
the Bonferroni post-hoc test.
Figure 4. Obatoclax mesylate overcomes TGF-β-induced chemo-resistance. (A) A549 cells were incubated with or without 5 ng/ml TGF-β for 48 h, shown 
as TGF-β or (-), respectively. Followed by the treatment with the indicated concentrations of obatoclax mesylate or 10 µM cisplatin for 48 h, cell viability 
was determined by CellTiter-Glo assay. Cell viability was normalized to that in each non-cisplatin/obatoclax-treated cells. **p<0.01 compared with TGF-β/
cisplatin-treated cells by one-way ANOVA followed by the Bonferroni post-hoc test. (B) Cisplatin (10 µM) or obatoclax mesylate (100 nM) were added after 
the incubation for 48 h with or without TGF-β. Other conditions are similar to (A). Whole cell lysates were subjected to western blotting.
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with our findings, it is reported that EMT can be observed 
in the tumor specimens resected from NSCLC patients after 
chemo-radiotherapy (14) to acquire chemo-resistance (14,16); 
therefore, these lines of evidence support a clinical relevance 
of our presented findings. Importantly, we have demonstrated 
the importance of pharmacological targeting of MCL-1 to 
re-sensitize cisplatin treatment in A549 cells. In addition to 
its importance in EMT-associated chemo-resistance shown 
in this study, MCL-1 is involved in anoikis-resistance in 
NSCLCs, which can be critical for the survival of tumor cells 
during the metastatic process (29).
In conclusion, we newly identified MCL-1 as a key 
molecule for acquiring EMT-associated chemo-resistance in 
human NSCLC. Considering EMT-associated MCL-1 induc-
tion might play critical roles not only in chemo-resistance, 
but also metastatic spread and survival in distant tissue, phar-
macological targeting of MCL-1 provides a new therapeutic 
opportunity in NSCLC particularly for combining with post-
operative chemotherapies.
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